CLINICAL TRIALS AND OBSERVATIONS Clinical profile of homozygous JAK2 617V F mutation in patients with polycythemia vera or essential thrombocythemia
نویسندگان
چکیده
Alessandro M. Vannucchi,1 Elisabetta Antonioli,1 Paola Guglielmelli,1 Alessandro Rambaldi,2 Giovanni Barosi,3 Roberto Marchioli,4 Rosa Maria Marfisi,4 Guido Finazzi,2 Vittoria Guerini,2 Fabrizio Fabris,5 Maria Luigia Randi,5 Valerio De Stefano,6 Sabrina Caberlon,7 Agostino Tafuri,8 Marco Ruggeri,9 Giorgina Specchia,10 Vincenzo Liso,10 Edoardo Rossi,11 Enrico Pogliani,12 Luigi Gugliotta,13 Alberto Bosi,1 and Tiziano Barbui,2 for the Italian Group for Malignant Hematologic Disorders of the Adult–Myeloproliferative Disorder Working Party (GIMEMA-MPD WP)
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
JAK2 V617F mutation recently was identified as a pathogenic factor in typical chronic myeloproliferative diseases (CMPD). Some forms of myelodysplastic syndromes (MDS) show a significant overlap with CMPD (classified as MDS/MPD), but the diagnostic assignment may be challenging. We studied blood or bone marrow from 270 patients with MDS, MDS/MPD, and CMPD for the presence of JAK2 V617F mutation...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V F) mutation
1Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia; 2Department of Medical and Surgical Sciences—Chirurgiche, Sezione Medicina Interna (CLOPD), University of Padova Medical School, Padova; 3Division of Hematology, Ospedale Niguarda Ca’ Granda, Milan; 4Department of Clinical Chemistry...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome
Sixty-four patients < 20 years of age, investigated for a suspicion of Philadelphianegative myeloproliferative disease (MPD), were retrospectively evaluated to characterize the different forms and to examine the treatments used and longterm outcome. JAK2 mutations, endogenous erythroid colony growth, and clonality were investigated in 51 children. Mutations of thrombopoietin, the thrombopoietin...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Leukocytes contribute to the pathogenesis of thrombosis in essential thrombocythemia (ET) through recently discovered mechanisms of activation and interaction with platelets and endothelial cells. To evaluate whether an increased leukocyte count was associated with thrombosis and whether this effect can be modulated by therapy, we analyzed the clinical course of 439 patients with ET followed at...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia (ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of new hematologic malignancies, but their risk of nonhematologic malignancies remains unknown. In the present study, we assessed the risk of both types of malignancies after an ET, PV, or CML diagnosis. We linked 2 popul...
متن کامل